These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 24018211)

  • 1. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
    Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Carretero G; Ribera M; Belinchón I; Carrascosa JM; Puig L; Ferrandiz C; Dehesa L; Vidal D; Peral F; Jorquera E; González-Quesada A; Muñoz C; Notario J; Vanaclocha F; Moreno JC;
    Actas Dermosifiliogr; 2013 Sep; 104(7):598-616. PubMed ID: 23891453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert report on psoriasis: Spanish dermatologists' opinions on the use of biologic agents to manage moderate to severe psoriasis in adults.
    Puig L; de la Cueva P; Linares M; Suarez J; Velasco M; Vidal D; Zulaica A; García-Calvo C
    Actas Dermosifiliogr; 2013 Jun; 104(5):400-8. PubMed ID: 23669590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
    Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
    J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents].
    Puig L; Carrascosa JM; Daudén E; Sánchez-Carazo JL; Ferrándiz C; Sánchez-Regaña M; García-Bustinduy M; Bordas X; Moreno JC; Hernanz JM; Laguarda S; García-Patos V;
    Actas Dermosifiliogr; 2009 Jun; 100(5):386-413. PubMed ID: 19558918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert recommendations on treating psoriasis in special circumstances.
    Carrascosa JM; Belinchón I; de-la-Cueva P; Izu R; Luelmo J; Ruiz-Villaverde R
    Actas Dermosifiliogr; 2015 May; 106(4):292-309. PubMed ID: 25595327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.
    Carrascosa JM; Puig L; Romero IB; Salgado-Boquete L; Del Alcázar E; Lencina JJA; Moreno D; de la Cueva P
    Actas Dermosifiliogr; 2022 Jun; 113(6):583-609. PubMed ID: 35570005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Daudén E; Puig L; Ferrándiz C; Sánchez-Carazo JL; Hernanz-Hermosa JM;
    J Eur Acad Dermatol Venereol; 2016 Mar; 30 Suppl 2():1-18. PubMed ID: 26812550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).
    Sánchez-Regaña M; Aldunce Soto MJ; Belinchón Romero I; Ribera Pibernat M; Lafuente-Urrez RF; Carrascosa Carrillo JM; Ferrándiz Foraster C; Puig Sanz L; Daudén Tello E; Vidal Sarró D; Ruiz-Villaverde R; Fonseca Capdevila E; Rodríguez Cerdeira MC; Alsina Gibert MM; Herrera Acosta E; Marrón Moya SE;
    Actas Dermosifiliogr; 2014 Dec; 105(10):923-34. PubMed ID: 24852726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
    Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
    Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy.
    Carrascosa JM; Puig L; Belinchón Romero I; Salgado-Boquete L; Del Alcázar E; Andrés Lencina JJ; Moreno D; de la Cueva P
    Actas Dermosifiliogr; 2022 Mar; 113(3):261-277. PubMed ID: 35526919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic agents in nail psoriasis: efficacy data and considerations.
    Kyriakou A; Patsatsi A; Sotiriadis D
    Expert Opin Biol Ther; 2013 Dec; 13(12):1707-14. PubMed ID: 24156504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C; García A; Blasco AJ; Lázaro P
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
    Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
    Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.